Dupilumab improves mental health measures in patients with chronic rhinosinusitis and nasal polyposis (CRSwNP)
C. Bachert (Ghent, Belgium), R. Naclerio (Chicago, United States of America), P. Hellings (Leuven, Belgium), S. Guillonneau (Chilly-Mazarin, France), C. Taniou (Nanterre, France), J. Maroni (Tarrytown, United States of America), P. Rowe (Bridgewater, United States of America), L. Mannent (Chilly-Mazarin, France), N. Amin (Tarrytown, United States of America), S. Kamat (Tarrytown, United States of America), A. Khan (Chilly-Mazarin, France)
Source: International Congress 2018 – Understanding the immunopathology that underlies airway obstructive diseases
Disease area: Airway diseases
Rating:
You must login to grade this presentation.
Share or cite this content
Citations should be made in the following way:
C. Bachert (Ghent, Belgium), R. Naclerio (Chicago, United States of America), P. Hellings (Leuven, Belgium), S. Guillonneau (Chilly-Mazarin, France), C. Taniou (Nanterre, France), J. Maroni (Tarrytown, United States of America), P. Rowe (Bridgewater, United States of America), L. Mannent (Chilly-Mazarin, France), N. Amin (Tarrytown, United States of America), S. Kamat (Tarrytown, United States of America), A. Khan (Chilly-Mazarin, France). Dupilumab improves mental health measures in patients with chronic rhinosinusitis and nasal polyposis (CRSwNP). 5004
You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
Related content which might interest you:
Related content which might interest you: